| COVID-19 pulmonary pathology: a multi-institutional autopsy cohort from Italy and New York City AC Borczuk, SP Salvatore, SV Seshan, SS Patel, JB Bussel, M Mostyka, ... Modern Pathology 33 (11), 2156-2168, 2020 | 483 | 2020 |
| Implications of the tumor immune microenvironment for staging and therapeutics JM Taube, J Galon, LM Sholl, SJ Rodig, TR Cottrell, NA Giraldo, AS Baras, ... Modern Pathology 31 (2), 214-234, 2018 | 332 | 2018 |
| Pembrolizumab in relapsed or refractory primary mediastinal large B-cell lymphoma P Armand, S Rodig, V Melnichenko, C Thieblemont, K Bouabdallah, ... Journal of Clinical Oncology 37 (34), 3291, 2019 | 251 | 2019 |
| PD-1 blockade with pembrolizumab for classical Hodgkin lymphoma after autologous stem cell transplantation P Armand, YB Chen, RA Redd, RM Joyce, J Bsat, E Jeter, RW Merryman, ... Blood, The Journal of the American Society of Hematology 134 (1), 22-29, 2019 | 159 | 2019 |
| Immunoregulatory roles of versican proteolysis in the myeloma microenvironment C Hope, S Foulcer, J Jagodinsky, SX Chen, JL Jensen, S Patel, C Leith, ... Blood, The Journal of the American Society of Hematology 128 (5), 680-685, 2016 | 141 | 2016 |
| The microenvironmental niche in classic Hodgkin lymphoma is enriched for CTLA-4–positive T cells that are PD-1–negative SS Patel, JL Weirather, M Lipschitz, A Lako, PH Chen, GK Griffin, ... Blood, The Journal of the American Society of Hematology 134 (23), 2059-2069, 2019 | 108 | 2019 |
| High NPM1-mutant allele burden at diagnosis predicts unfavorable outcomes in de novo AML SS Patel, FC Kuo, CJ Gibson, DP Steensma, RJ Soiffer, EP Alyea III, ... Blood, The Journal of the American Society of Hematology 131 (25), 2816-2825, 2018 | 80 | 2018 |
| PD-1 blockade for diffuse large B-cell lymphoma after autologous stem cell transplantation MJ Frigault, P Armand, RA Redd, E Jeter, RW Merryman, KC Coleman, ... Blood Advances 4 (1), 122-126, 2020 | 58 | 2020 |
| Clinicopathologic and genetic characterization of nonacute NPM1-mutated myeloid neoplasms SS Patel, C Ho, RN Ptashkin, S Sadigh, A Bagg, JT Geyer, ML Xu, ... Blood advances 3 (9), 1540-1545, 2019 | 51 | 2019 |
| Primary effusion lymphoma S Patel, P Xiao Archives of Pathology and Laboratory Medicine 137 (8), 1152-1154, 2013 | 50 | 2013 |
| Genomic and clinical characterization of B/T mixed phenotype acute leukemia reveals recurrent features and T‐ALL like mutations X Mi, G Griffin, W Lee, S Patel, R Ohgami, CY Ok, S Wang, JT Geyer, ... American journal of hematology 93 (11), 1358-1367, 2018 | 45 | 2018 |
| Overview of tissue imaging methods SS Patel, SJ Rodig Biomarkers for immunotherapy of cancer: methods and protocols, 455-465, 2020 | 25 | 2020 |
| High NPM1 mutant allele burden at diagnosis correlates with minimal residual disease at first remission in de novo acute myeloid leukemia SS Patel, GS Pinkus, LL Ritterhouse, JP Segal, P Dal Cin, T Restrepo, ... American journal of hematology 94 (8), 921-928, 2019 | 25 | 2019 |
| Intestinal abnormalities in patients with SARS-CoV-2 infection: histopathologic changes reflect mechanisms of disease RK Yantiss, LH Qin, B He, CV Crawford, S Seshan, S Patel, N Wahid, ... The American Journal of Surgical Pathology 46 (1), 89-96, 2022 | 23 | 2022 |
| Pembrolizumab in patients with relapsed or refractory primary mediastinal large B-cell lymphoma (PMBCL): data from the Keynote-013 and Keynote-170 studies P Armand, SJ Rodig, V Melnichenko, C Thieblemont, K Bouabdallah, ... Blood 132, 228, 2018 | 21 | 2018 |
| Diagnostic workup of acute leukemias of ambiguous lineage SS Patel, OK Weinberg American Journal of Hematology 95 (6), 718-722, 2020 | 15 | 2020 |
| Hyalinizing trabecular tumor of the thyroid gland and its significant diagnostic issue DJ Jones, CR Kieliszak, SS Patel, CR Selinsky Thyroid Research 10, 1-5, 2017 | 15 | 2017 |
| Constitutive Ras signaling and Ink4a/Arf inactivation cooperate during the development of B-ALL in mice T Sewastianik, M Jiang, K Sukhdeo, SS Patel, K Roberts, Y Kang, ... Blood advances 1 (25), 2361-2374, 2017 | 14 | 2017 |
| PKCλ/ι inhibition activates an ULK2-mediated interferon response to repress tumorigenesis JF Linares, X Zhang, A Martinez-Ordoñez, A Duran, H Kinoshita, ... Molecular cell 81 (21), 4509-4526. e10, 2021 | 13 | 2021 |
| Comparison of multiple clinical testing modalities for assessment of NPM1-mutant AML A Lopez, S Patel, JT Geyer, J Racchumi, A Chadburn, P Simonson, ... Frontiers in Oncology 11, 701318, 2021 | 13 | 2021 |
Scott RodigProfessor of Pathology, Brigham & Women's HospitalVerified email at bwh.harvard.edu
